Constitution of a Biobank for Studies Related to Organ Transplantation (Lyon Centaure Biocollection)
NCT ID: NCT04687865
Last Updated: 2025-03-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
4000 participants
OBSERVATIONAL
2020-01-08
2040-01-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
i) validate new theory on the cause of allograft loss, ii) develop innovative biomarker for rejection and other transplantation-related conditions (such as BK virus nephropathy, Post-transplant lymphoproliferative disorder ( PTLD) ...)
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
BIOBANK Renal Transplantation University Hospitals Leuven
NCT01331668
Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
NCT03723668
Vaccines Immunogenicity in Renal, Hepatic, Cardiac or Pulmonary Transplanted Children
NCT03180359
Changes in the Microbiome Associated With Transplantation
NCT04280627
TTV-based mAnagement Of Long-term ImmunosuppreSsion in Kidney Transplantation
NCT06829719
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Biobank
For each patient included in the study the following samples will be collected at the indicated time points after transplantation:
* Serum samples and plasma sample: Day1, Month 1, Month 3, Month 6, Month 12, month 60, month 120 and at the time of each allograft biopsy.
* Urines samples: Month 3 and Month 12 and at the time of each allograft biopsy.
* Peripheral Blood Mononuclear Cell (PBMC): for each organ allograft biopsy.
* Allograft biopsies: systematically at Month 3, and Month 12, and for cause in case of allograft dysfunction.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Recipient of an organ transplant
* Written informed consent
Exclusion Criteria
* Subjects deprived of liberties
* Pregnant or breastfeeding woman
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olivier Thaunat, MD
Role: PRINCIPAL_INVESTIGATOR
Edouard Herriot Hospital - Transplantation department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hopital Edouard Herriot
Lyon, Rhône, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL20_0964
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.